Myriad Genetics (NASDAQ:MYGN) Issues Q4 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided EPS guidance of $0.03-0.04 for the period, compared to the consensus EPS estimate of $0.03. The company issued revenue guidance of $209-211 million, compared to the consensus revenue estimate of $212.87 million. Myriad Genetics also updated its FY25 guidance to $0.07-0.11 EPS.

Myriad Genetics Price Performance

Shares of MYGN stock opened at $13.68 on Wednesday. The stock has a 50 day moving average price of $15.05 and a 200 day moving average price of $22.17. Myriad Genetics has a 52-week low of $12.87 and a 52-week high of $29.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The firm has a market capitalization of $1.25 billion, a P/E ratio of -10.52 and a beta of 1.89.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MYGN shares. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a report on Thursday, January 9th. Leerink Partnrs downgraded shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. UBS Group assumed coverage on shares of Myriad Genetics in a research note on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price target for the company. Leerink Partners downgraded Myriad Genetics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $30.00 to $21.00 in a report on Monday, December 9th. Finally, Bank of America reduced their price objective on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a report on Friday, December 13th. Three analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Myriad Genetics presently has a consensus rating of “Hold” and an average price target of $24.27.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.